Related Experiment Video
Updated: Jul 5, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous
Athanasia Katsoulas1, Zakaria Rachid, James P McNamee
1Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, 687 Pine Avenue West, M7.19, Montreal, Quebec, Canada H3A 1A1.
Abstract:
Blockade of Bcr-Abl by the inhibitor Imatinib has proven efficacious in the therapy of chronic myelogenous leukemia (CML). However resistance to the drug emerges at the advanced phases of the disease. Therefore, novel therapy models remained to be designed. We have developed a novel dual targeted agent termed "combi-molecule" designed to not only block Bcr-Abl but also damage DNA. ZRF1, the first optimized prototype of the approach, was "programmed" to degrade into another inhibitor ZRF0 plus a methyl diazonium species. It was approximately 2-fold stronger Abl tyrosine kinase inhibitor than Imatinib and a more potent DNA-damaging agent than Temodal. In the p53 wild-type Mo7p210 cells, the potency of ZRF1 was approximately 1,000-fold superior to that of the equieffective combinations of Imatinib plus Temodal. More importantly, its superior potency over Imatinib was more pronounced in Bcr-Abl-positive cells coexpressing wild-type p53. Studies to rationalize these results showed that, through its Bcr-Abl inhibitory function, it down-regulated p53. However, sufficient level of the latter protein was available for transactivating p21 and Bax, which are required for cell cycle arrest and apoptosis. The results suggest that, in p53 wild-type cells, apoptosis is induced not only through Bcr-Abl inhibition but also through the p53-controlled DNA-damaging pathway, leading to an additive effect that translates into enhanced cell death. The study conclusively showed that p53 is a major determinant for the cytotoxic advantages of the novel combi-molecular approach in CML, a disease in which 70% to 85% of all the cases express wild-type p53.
Insights
A novel dual-targeted agent, ZRF1, effectively treats chronic myelogenous leukemia (CML) by inhibiting Bcr-Abl and damaging DNA. It shows superior efficacy in p53 wild-type cells, offering a promising new CML therapy model.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Imatinib is effective against chronic myelogenous leukemia (CML) by blocking Bcr-Abl.
- Drug resistance to Imatinib emerges in advanced CML phases, necessitating novel therapeutic strategies.
- The role of p53 in CML treatment response requires further elucidation.
Purpose of the Study:
- To develop and evaluate a novel dual-targeted agent (combi-molecule) for CML treatment.
- To assess the efficacy of ZRF1, a prototype combi-molecule, in inhibiting Bcr-Abl and inducing DNA damage.
- To investigate the role of p53 in mediating the cytotoxic effects of ZRF1 in CML cells.
Main Methods:
- Development of ZRF1, a combi-molecule designed to inhibit Bcr-Abl and damage DNA.
- In vitro assessment of ZRF1's inhibitory activity against Abl tyrosine kinase compared to Imatinib.
- Evaluation of ZRF1's DNA-damaging potential compared to Temozolomide.
- Comparative efficacy studies of ZRF1, Imatinib, and Temozolomide in p53 wild-type CML cell lines (Mo7p210).
Main Results:
- ZRF1 demonstrated approximately 2-fold greater Abl tyrosine kinase inhibition than Imatinib.
- ZRF1 exhibited more potent DNA-damaging activity than Temozolomide.
- In p53 wild-type Mo7p210 cells, ZRF1 was approximately 1,000-fold more potent than equivalent combinations of Imatinib and Temozolomide.
- The superior efficacy of ZRF1 was more pronounced in Bcr-Abl-positive cells with wild-type p53.
- ZRF1's mechanism involves Bcr-Abl inhibition leading to p53 downregulation, followed by p53-mediated transactivation of p21 and Bax, inducing cell cycle arrest and apoptosis.
Conclusions:
- ZRF1 represents a novel and highly potent therapeutic agent for CML, particularly in p53 wild-type cases.
- The dual-targeting approach of ZRF1, combining Bcr-Abl inhibition with DNA damage, leads to enhanced cell death through an additive effect.
- p53 is a critical determinant of the enhanced cytotoxic efficacy of this novel combi-molecular strategy in CML, where wild-type p53 is prevalent.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted